Kopran Reports ₹99.2 Million Loss In Q2 Despite ₹1.18 Billion Revenue

Kopran Ltd., a pharmaceutical company specializing in APIs and finished dosage formulations, announced its Q2 FY26 financial results with consolidated revenue from operations at ₹1.18 billion and a net loss of ₹99.2 million. The results reflect ongoing challenges in export markets and cost inflation, impacting profitability despite stable topline performance.

The company remains committed to strengthening its product pipeline and operational efficiency.

Major Takeaways From The Quarterly Update: 

• Revenue from operations stood at ₹1.18 billion, reflecting stable domestic demand  
• Net loss of ₹99.2 million attributed to higher operating expenses and export headwinds  
• Operating income declined 23.8 percent quarter-on-quarter to ₹10.88 crore  
• Total operating expenses rose 12.4 percent QoQ, driven by input cost inflation  
• Kopran continues to invest in R&D for high-margin therapeutic categories  
• Management is focused on improving plant utilization and cost rationalization  
• Strategic reviews are underway to enhance export competitiveness and regulatory compliance

Kopran’s Q2 performance highlights near-term pressures but signals continued efforts to build a resilient pharmaceutical portfolio.

Sources: Kopran Financials, Mint Q2 Results, Economic Times